RARE

43.78

2.17% -0.97

Dopo l'orario di chiusura: 43.78

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RARE Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$44.75

Aprire:

$44.5

Volume 24 ore:

1.04M

Relative Volume:

1.45

Capitalizzazione di mercato:

$4.03B

Reddito:

$522.75M

Utile/perdita netta:

$-558.99M

Rapporto P/E:

-4.8807

EPS:

-8.97

Flusso di cassa netto:

$-492.48M

1 W Prestazione:

-13.70%

1M Prestazione:

-22.18%

6M Prestazione:

+4.56%

1 anno Prestazione:

+9.53%

Intervallo 1D:

$43.04

$44.92

Intervallo di 1 settimana:

$43.04

$50.48

Portata 52W:

$37.02

$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Nome

Ultragenyx Pharmaceutical Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

415-483-8800

Indirizzo

60 LEVERONI COURT, NOVATO, CA

Dipendente

1,276

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

RARE's Discussions on Twitter

Confronta RARE con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RARE	43.78	4.03B	522.75M	-558.99M	-492.48M	-8.97
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-06-06	Aggiornamento	Evercore ISI	In-line → Outperform
2023-04-26	Iniziato	Cantor Fitzgerald	Overweight
2023-01-18	Ripresa	Canaccord Genuity	Buy
2022-12-30	Ripresa	H.C. Wainwright	Buy
2022-11-03	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-01	Downgrade	Evercore ISI	Outperform → In-line
2022-03-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2022-02-11	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-30	Iniziato	H.C. Wainwright	Buy
2021-08-19	Iniziato	UBS	Sell
2021-07-15	Iniziato	Guggenheim	Neutral
2021-06-29	Aggiornamento	BofA Securities	Neutral → Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	Citigroup	Neutral → Buy
2021-05-06	Aggiornamento	Evercore ISI	In-line → Outperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-02	Ripresa	Stifel	Buy
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-07	Downgrade	Wedbush	Outperform → Neutral
2020-11-24	Ripresa	Evercore ISI	In-line
2020-11-12	Downgrade	BofA Securities	Buy → Neutral
2019-08-02	Ripresa	Wedbush	Outperform
2019-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-08	Aggiornamento	Citigroup	Sell → Neutral
2018-09-10	Iniziato	Morgan Stanley	Equal-Weight
2018-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2018-05-11	Aggiornamento	Barclays	Equal Weight → Overweight
2018-05-10	Iniziato	Goldman	Neutral
2018-04-18	Aggiornamento	SunTrust	Hold → Buy
2018-03-22	Ripresa	Piper Jaffray	Overweight
2018-02-21	Reiterato	Stifel	Buy
2018-01-22	Aggiornamento	Evercore ISI	In-line → Outperform
2018-01-18	Iniziato	Credit Suisse	Outperform
2017-12-05	Reiterato	Barclays	Equal Weight
2017-12-04	Aggiornamento	Jefferies	Hold → Buy
2017-09-14	Aggiornamento	Wedbush	Neutral → Outperform

Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

03:54 AM

State of New Jersey Common Pension Fund D Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

03:54 AM

Nov 15, 2024

Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR

Nov 15, 2024

Nov 14, 2024

How To Trade (RARE) - Stock Traders Daily

Nov 14, 2024

RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com

Nov 13, 2024

Nov 12, 2024

Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN

Nov 12, 2024

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat

Nov 12, 2024

Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha

Nov 12, 2024

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024

Nov 11, 2024

Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 10, 2024

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN

Nov 10, 2024

Nov 09, 2024

Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha

Nov 09, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire

Nov 09, 2024

Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan

Nov 09, 2024

Nov 08, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat

Nov 07, 2024

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024

Nov 06, 2024

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India

Nov 06, 2024

HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat

Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa

Nov 06, 2024

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga

Nov 06, 2024

International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 06, 2024

Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha

Nov 06, 2024